FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2696309480> ?p ?o ?g. }

• W2696309480 endingPage "1395.e4" @default.
• W2696309480 startingPage "1380" @default.
• W2696309480 abstract "PurposeAlmost half of all patients diagnosed with schizophrenia have a history of substance abuse (SA). However, data on treatment of schizophrenia with paliperidone palmitate (PP) among patients with comorbid SA are limited. The objective of this study was to compare all-cause and SA-related health care resource utilization and costs in veterans with schizophrenia and co-occurring SA who were treated with PP versus oral atypical antipsychotics (OAAs).MethodsVeterans Health Administration electronic health record data were used to conduct a retrospective longitudinal study in veterans with schizophrenia who initiated PP or OAA between January 1, 2010 and June 30, 2016, had ≥12 months of enrollment before treatment initiation (baseline), were diagnosed with SA, and had ≥1 Global Assessment of Functioning score during baseline. Differences in baseline characteristics were adjusted for using inverse probability of treatment weighting. Adjusted cost differences and incidence rate ratios (IRR) for the association between PP versus OAA and all-cause and SA-related health care costs and health care resource utilization in the 12 months after treatment initiation were estimated with corresponding 95% CIs using weighted linear and Poisson regression models, respectively.FindingsOf 6872 veterans in the study, 1684 (25%) and 5188 (75%) were treated with PP and OAA, respectively. After adjustment, PP was associated with fewer all-cause inpatient (IRR = 0.88; 95% CI, 0.85 to 0.90), mental health-related inpatient (IRR = 0.88; 95% CI, 0.85 to 0.91), and long-term care stays (IRR = 0.53; 95% CI, 0.44 to 0.64), but more frequent mental health intensive case management visits (IRR = 1.51; 95% CI, 1.49 to 1.53) compared with OAA (all P < 0.001). Similarly, PP was associated with significantly lower rates of SA-related inpatient stays (IRR = 0.80; 95% CI, 0.77 to 0.83), mental health stays (IRR = 0.85; 95% CI, 0.82 to 0.88), long-term care stays (IRR = 0.22; 95% CI, 0.15 to 0.32), and outpatient visits (IRR = 0.78; 95% CI, 0.77 to 0.79) than OAA (all P < 0.001). Relative to OAA, patients treated with PP also had lower mean annual all-cause (cost difference = −$10,473; 95% CI, −$17,827 to −$3491) and SA-related (cost difference = −$8457; 95% CI, −$12,710 to −$3638) medical costs (all P < 0.001).ImplicationsPP was associated with significant total medical cost savings resulting from fewer hospitalizations and lower rates of SA-related health care resource utilization compared with OAA in patients with schizophrenia and comorbid SA. Thus, PP appears to be a valuable treatment option for patients in this subpopulation." @default.
• W2696309480 created "2017-06-30" @default.
• W2696309480 creator A5011177968 @default.
• W2696309480 creator A5019269759 @default.
• W2696309480 creator A5020038170 @default.
• W2696309480 creator A5049944206 @default.
• W2696309480 creator A5063896009 @default.
• W2696309480 creator A5070476741 @default.
• W2696309480 creator A5084091780 @default.
• W2696309480 creator A5084952345 @default.
• W2696309480 date "2017-07-01" @default.
• W2696309480 modified "2023-10-10" @default.
• W2696309480 title "Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse" @default.
• W2696309480 cites W2003359484 @default.
• W2696309480 cites W2008557562 @default.
• W2696309480 cites W2009187570 @default.
• W2696309480 cites W2013352671 @default.
• W2696309480 cites W2063563315 @default.
• W2696309480 cites W2077009364 @default.
• W2696309480 cites W2093484512 @default.
• W2696309480 cites W2105527159 @default.
• W2696309480 cites W2112786802 @default.
• W2696309480 cites W2113687724 @default.
• W2696309480 cites W2125789790 @default.
• W2696309480 cites W2126049444 @default.
• W2696309480 cites W2128438886 @default.
• W2696309480 cites W2132689140 @default.
• W2696309480 cites W2143855802 @default.
• W2696309480 cites W2145516695 @default.
• W2696309480 cites W2146520900 @default.
• W2696309480 cites W2155945003 @default.
• W2696309480 cites W2168444309 @default.
• W2696309480 cites W2171396692 @default.
• W2696309480 cites W2286111 @default.
• W2696309480 cites W2512163677 @default.
• W2696309480 doi "https://doi.org/10.1016/j.clinthera.2017.05.356" @default.
• W2696309480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28641996" @default.
• W2696309480 hasPublicationYear "2017" @default.
• W2696309480 type Work @default.
• W2696309480 sameAs 2696309480 @default.
• W2696309480 citedByCount "18" @default.
• W2696309480 countsByYear W26963094802018 @default.
• W2696309480 countsByYear W26963094802019 @default.
• W2696309480 countsByYear W26963094802020 @default.
• W2696309480 countsByYear W26963094802021 @default.
• W2696309480 countsByYear W26963094802022 @default.
• W2696309480 countsByYear W26963094802023 @default.
• W2696309480 crossrefType "journal-article" @default.
• W2696309480 hasAuthorship W2696309480A5011177968 @default.
• W2696309480 hasAuthorship W2696309480A5019269759 @default.
• W2696309480 hasAuthorship W2696309480A5020038170 @default.
• W2696309480 hasAuthorship W2696309480A5049944206 @default.
• W2696309480 hasAuthorship W2696309480A5063896009 @default.
• W2696309480 hasAuthorship W2696309480A5070476741 @default.
• W2696309480 hasAuthorship W2696309480A5084091780 @default.
• W2696309480 hasAuthorship W2696309480A5084952345 @default.
• W2696309480 hasBestOaLocation W26963094801 @default.
• W2696309480 hasConcept C118552586 @default.
• W2696309480 hasConcept C126322002 @default.
• W2696309480 hasConcept C134362201 @default.
• W2696309480 hasConcept C160735492 @default.
• W2696309480 hasConcept C162324750 @default.
• W2696309480 hasConcept C167135981 @default.
• W2696309480 hasConcept C167704817 @default.
• W2696309480 hasConcept C194828623 @default.
• W2696309480 hasConcept C2776412080 @default.
• W2696309480 hasConcept C2777126507 @default.
• W2696309480 hasConcept C2780494398 @default.
• W2696309480 hasConcept C2908647359 @default.
• W2696309480 hasConcept C2908997079 @default.
• W2696309480 hasConcept C40010229 @default.
• W2696309480 hasConcept C44249647 @default.
• W2696309480 hasConcept C50522688 @default.
• W2696309480 hasConcept C71924100 @default.
• W2696309480 hasConcept C73269764 @default.
• W2696309480 hasConcept C99454951 @default.
• W2696309480 hasConceptScore W2696309480C118552586 @default.
• W2696309480 hasConceptScore W2696309480C126322002 @default.
• W2696309480 hasConceptScore W2696309480C134362201 @default.
• W2696309480 hasConceptScore W2696309480C160735492 @default.
• W2696309480 hasConceptScore W2696309480C162324750 @default.
• W2696309480 hasConceptScore W2696309480C167135981 @default.
• W2696309480 hasConceptScore W2696309480C167704817 @default.
• W2696309480 hasConceptScore W2696309480C194828623 @default.
• W2696309480 hasConceptScore W2696309480C2776412080 @default.
• W2696309480 hasConceptScore W2696309480C2777126507 @default.
• W2696309480 hasConceptScore W2696309480C2780494398 @default.
• W2696309480 hasConceptScore W2696309480C2908647359 @default.
• W2696309480 hasConceptScore W2696309480C2908997079 @default.
• W2696309480 hasConceptScore W2696309480C40010229 @default.
• W2696309480 hasConceptScore W2696309480C44249647 @default.
• W2696309480 hasConceptScore W2696309480C50522688 @default.
• W2696309480 hasConceptScore W2696309480C71924100 @default.
• W2696309480 hasConceptScore W2696309480C73269764 @default.
• W2696309480 hasConceptScore W2696309480C99454951 @default.
• W2696309480 hasIssue "7" @default.
• W2696309480 hasLocation W26963094801 @default.
• W2696309480 hasLocation W26963094802 @default.

• next